Professor Zhengming Chen
- Assessment of the role of EBV infection in aetiology of nasopharyngeal and gastric cancers in Chinese adults CRUK STUDENTSHIP AVAILABLE
- Bone mineral density and osteoporosis: patterns, determinants and their relationships with cardiometabolic disorders in Chinese adults
- Burden and risk factors of infectious complications among Chinese adults with diabetes (MRC PHRU)
- Burden and risk factors of infectious complications among Chinese adults with diabetes
- Chronic infection, host immunity and risk of cancer (MRC PHRU)
- Development of cardiovascular risk prediction model for Chinese adults
- Diabetes and risk of cancer in diverse populations. CRUK SCHOLARSHIP AVAILABLE
- Epidemiology of autoimmune disease in Chinese adults
- Female reproductive history and risks of cancer and other diseases in a prospective cohort study of 300,000 Chinese women
- Medical Research Council Population Health Research Unit (MRC PHRU)
- Patterns and risk factors of arthritis, fractures and other musculoskeletal disorders in 0.5 million Chinese adults
- Phenome-wide association studies of functional genetic variants to validate drug targets (MRC PHRU)
- Phenome-wide association studies of functional genetic variants to identify and validate drug targets
- Physical activity and risk of non-vascular chronic diseases in Chinese men and women
Professor of Epidemiology and Director of China Programmes
- Clinical Trial Service Unit and Epidemiological Studies Unit
Professor Zhengming Chen qualified in medicine at Shanghai Medical University in 1983 (now Fudan University), and gained his DPhil in Epidemiology at the University of Oxford in 1993. He was appointed as Professor of Epidemiology by the University of Oxford in 2006. He is now the Director of the China Programs at the Oxford University’s Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) and co-executive director of the China Oxford Centre for International Health Research. His main researches focus on the environmental and genetic causes of chronic disease, evidence-based medicine and evaluation of widely practicable treatments for chronic diseases (such as IHD, stroke and cancer) as well as efficient strategies for chronic disease control in developing countries. Over the past 20 years, he has led several large randomised trials in heart disease (eg, COMMIT/CCS-2), stroke (eg, CAST) and cancer and 3 cohort studies involving >750,000 individuals. Since 2003 he has been the lead principal investigator in the UK for the China Kadoorie Biobank (CKB) prospective study of 0.5 million adults. He leads a research team in Oxford which is responsible for study design and development of procedures and IT systems for the CKB, and for central data management, curation and detailed analyses. He is an honorary professor of Peking Union Medical College and Fudan University in China.
Improved prediction of fracture risk leveraging a genome-wide polygenic risk score
Lu T. et al, (2021), Genome Medicine, 13
Author Correction: Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors.
Bakker MK. et al, (2020), Nat Genet
Blood pressure and cardiovascular diseases in Chinese adults with type 2 diabetes: a prospective cohort study
BRAGG F. et al, (2020), The Lancet Regional Health - Western Pacific
Feasibility and validity of using death surveillance data and SmartVA for fact and cause of death in clinical trials in rural China: a substudy of the China salt substitute and stroke study (SSaSS).
Huang L. et al, (2020), J Epidemiol Community Health
Associations of Adiposity, Circulating Protein Biomarkers, and Risk of Major Vascular Diseases.
Pang Y. et al, (2020), JAMA Cardiol